在2019-2023年对95种差异化甲状腺癌/形甲状腺癌的个性化治疗

Nai-Si Huang1,2, Jia-Ying Chen1,2, Wen-Jun Wei1,2

  • 1Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

European thyroid journal
|October 17, 2025
PubMed
概括

积极的治疗,包括新辅助疗法,显著改善了差差分化甲状腺癌 (PDTC) 和形甲状腺癌 (ATC) 患者的生存率. 个性化治疗策略对于在这些罕见和积极的甲状腺癌中获得更好的结果至关重要.

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K